GlassScriptPhysician profile
Alexandrea Orange
NPI 1518585066
$684.64
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.46 · 2022: $244 · 2023: $272 · 2024: $77.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $282.51 | 2021-2024 | Mitris Resilia Mitral Valve, Konect Resilia, Inspiris Resilia Aortic Valve |
| Atricure, INC. | $178.92 | 2022-2024 | |
| W. L. Gore & Associates, INC. | $37.80 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Shockwave Medical, INC | $27.74 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Corcym INC | $26.37 | 2023 | Perceval |
| Getinge USA Sales, LLC | $25.21 | 2023 | Vasoview Hemopro 2 |
| Merck Sharp & Dohme LLC | $23.65 | 2024 | Keytruda |
| Angiodynamics, INC. | $21.81 | 2022 | |
| Olympus America INC. | $20.54 | 2023 | 4k Cable 8.5m, Evis Exera III Bronchovideoscope, Evis Exera II Ultrasonic Bronchofibervideoscope |
| Astrazeneca Pharmaceuticals LP | $20.15 | 2023 | Tagrisso |
| Chiesi USA, INC. | $19.94 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandrea Orange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.